Ligand Licenses OmniAb Platform to Sanofi
December 02 2019 - 12:14PM
Dow Jones News
By Colin Kellaher
Ligand Pharmaceuticals Inc. (LGND) Monday said it signed a
worldwide license agreement for its OmniAb antibody discovery
platform with Paris drug maker Sanofi S.A. (SAN.FR, SNY).
The San Diego biopharmaceutical company said Sanofi will pay an
undisclosed upfront platform access fee, along with development and
regulatory milestone payments and potential royalties on sales of
marketed products.
Ligand said it has licensed OmniAb to more than 40 companies
around the world.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 02, 2019 11:59 ET (16:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024